BioCorRx Inc. announced the addition of Dr. Ashok Kumar MSc DIoD FRCPath, Michael Howcroft, Priya Jambhekar, and Dr. Jeff Witkin to its scientific advisory board. The new board members raise the number of company advisors to seven. The additional SAB members are as follows: Dr. Jeff Witkin is a Research Fellow with RespireRx Inc., and the co-founder of the Laboratory of Antiepileptic Drug Discovery where he holds a research appointment at Ascension St. Vincent Hospital in Indianapolis, Indiana. He is an Adjunct Professor in the Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI. He heads the Witkin Consulting Group that advises companies working on the development of novel therapeutics in the areas of neurology and psychiatry. He is also one of the founders of Gilgamesh Pharmaceuticals based in New York, NY. Priya Jambhekar is a drug development entrepreneur with over 25 years of executive experience in worldwide regulatory, quality, clinical and pharmacovigilance operations, as well as early and late-stage development product registration and commercial support. She has held positions including Global Senior Vice President of Regulatory & Quality Operations at Paramount BioSciences, Global Vice President at Ethicon, a Johnson & Johnson company, and Worldwide Vice President of Regulatory and Government Relations at Alkermes. Other senior positions include Baxter ACC, as Regulatory Head of Compliance, and Bristol-Myers Squibb, as Manager of Regulatory, Safety, Compliance. Dr. Ashok Kumar MSc DIoD FRCPath has over 25 years’ experience in drug delivery development and production. Dr. Kumar is a serial entrepreneur following his early days in a clinical and research environment. His experience spans not only in the research of drug delivery but actually turning the projects from the laboratory setting into production and delivering the results directly to the patient. His work in planning and procurement has allowed him to head a number of pharmaceutical companies with a keen interest in substance dependency and its management. As a result, he has spent the best part of 20 years working on developing and improving naltrexone implantable technology in conjunction with the end users. Dr. Kumar has worked on various formulation for extended release and continues to be regarded as one of the key individuals in his field. Michael Howcroft is currently a consulting pharmacist. Howcroft was a co-founder of one of the first Pharmacy Benefit Management Companies, currently known as Anthem. Howcroft’s experience is in drug formulary management, preferred drug list management, rebate contracting, outcomes and value-based contracts, benefit analysis and design, disease state management, drug utilization review management, data analysis, experience in writing legislative administrative code policies, an acute understanding of medical and pharmacy coding, management of the pharmacy and therapeutics committee and drug utilization review board. Howcroft also has experience in hospital pharmacy, retail pharmacy, oncology, and home infusion. He has worked with major companies in commercial insurance, self-employed insurance, managed care and most recently Medicaid/Medicare. Howcroft also served as secretary to the Chief Medical Officer in the development and implementation of the Ohio Governor’s Cabinet Opiate Action Team (GCOAT) which developed policies in Ohio for Opioid prescribing guidelines.